PharmaEssentia Corporation

PharmaEssentia Corporation, a biopharmaceutical company provides medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan.

Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. It also develops Ropeg + anti PD-1.

Its portfolio also includes PEG-IL-2 (P11838), PEG-Cytokines, PD-1-IL-2v, ADC, ADCS, NY-ESO-1 TCR-T, and Novel TCR-T for the treatment of solid tumor and immunology. Founded in 1990, PharmaEssentia is headquartered in Taipei, Taiwan.